Background. Rapid diagnostic tests (RDTs) are an important tool for malaria diagnosis, with most using antibodies against Plasmodium falciparum histidine-rich protein 2 (PfHRP2). Reports of P. falciparum lacking this protein are increasing, creating a problem for diagnosis of falciparum malaria in locations without quality-assured microscopy.
Accurate diagnosis of malaria, a disease infecting >200 million persons annually, is fundamental for its control [1] . As malaria incidence falls owing to ongoing investment toward elimination, correct diagnosis and case management of nonmalaria fever cases will become even more important [2] . Community-based early diagnosis and treatment services have been deployed in numerous locations, with free access to reliable rapid diagnostic tests (RDTs) and effective treatment for all clinical malaria cases in a region being key to their success [3] .
The World Health Organization (WHO) recommends parasitological confirmation before treatment for malaria with quality-assured microscopy or RDTs [4] . Since this recommendation was published, RDT sales have increased >6-fold, with an associated reduction in prescribing or purchasing of antimalarial drugs [1, 5] . A meta-analysis of data from community surveys showed RDTs to have detection capability comparable to that of routine microscopy, and often better [6] . RDTs with increased sensitivity are also being developed for elimination efforts where focal mass screening and treatment are being considered.
The majority of commercially available RDTs that diagnose Plasmodium falciparum target P. falciparum histidine-rich protein 2 (PfHRP2) [7] . Performance testing of RDTs revealed PfHRP2 to be a more sensitive antigen for detecting P. falciparum than other antigens, such as Plasmodium lactate dehydrogenase (pLDH) [8] . P. falciparum also produces P. falciparum histidine-rich protein 3 (PfHRP3), an antigen highly similar to PfHRP2. Neither PfHRP2 nor PfHRP3 are essential for P. falciparum survival or transmission, with parasites lacking one or both of the antigen-coding genes detected in field isolates. PfHRP2/3-negative parasites were first reported in Peru [9] and have now been confirmed to exist in multiple locations within South America and India, at high (>20%) prevalence [10, 11] . Parasites lacking either or both PfHRP2/3 have also been reported in Mali, Senegal, and Ghana [10] .
The presence of PfHRP2-negative parasites presents a significant problem for the diagnosis of malaria by RDT, especially for Africa where P. falciparum is predominant and PfHRP2-detecting P. falciparum-only RDTs are used. PfHRP2/3-negative parasites can emerge when local parasites undergo a deletion event, or they can be introduced. Both scenarios have occurred in South America [12] [13] [14] . Although the force of selection is unclear, parasites lacking PfHRP2/3 must have advantage under selection to become prevalent and a public health problem, as observed in Peru [9, 15] .
The current study investigated whether RDT usage alone is sufficient to select parasites lacking PfHRP2 in communities using a mathematical model. The model tracks the life course of parasites to determine the likelihood of establishment in the community and monitors subsequent effects on malaria's morbid effects and transmission within the community.
METHODS
An agent-based simulation model encompassing both the within-host dynamics and transmission of P. falciparum was used to investigate the spread of an introduced parasite into a hypothetical village of 400 persons ( Figure 1 ). The model is based on the previously reported work of Gatton and Cheng [16] , with modification to how diagnosis and treatment of symptomatic infections occurs. Full model details are contained in the Supplementary Materials.
Treatment Seeking and Diagnosis
It is assumed that either 50% or 80% of individuals who have a fever caused by malaria seek treatment. The time to treatment for each individual is drawn from an empirical distribution, parameterized such that 75% of individuals seeking treatment do so within 3 days of onset of fever (Supplemental Materials) [17, 18] . Diagnosis with RDT is performed on the treatment day. Two RDT types are considered, an RDT that detects only PfHRP2 (RDT1) and a combination RDT that targets both PfHRP2 and P. falciparum-specific-pLDH (RDT2).
Within the model, the PfHRP2 and P. falciparum-pLDH antigen levels in each host are tracked daily. Antigen levels are expressed as "equivalent parasites, " with antigen decay considered a first-order process and with half-lives of 3.67 and 1.84 days for PfHRP2 and pLDH, respectively [19, 20] . The probability that an RDT result will be positive is related to the simulated antigen level in the host, with the probability informed by the patterns observed for RDTs meeting the WHO procurement criteria [7] (Supplementary Table 1 ).
The RDT is the sole diagnostic included in the model, with only RDT-positive patients receiving antimalarial treatment. This reflects the situation in many remote and hard-to-reach communities where community health workers are engaged to diagnose and treat malaria cases.
Drug Dynamics After Treatment
Two artemisinin-combination therapies (ACTs), artesunatemefloquine (MQ) and artemether-lumefantrine (LF; Coartem), were simulated to capture partner drugs with long and short half-lives. Partner drug pharmacokinetics were adopted from Simpson et al [21] for MQ and Stepniewska and White [22] for LF. Throughout the article, ACTs are identified by the partner drug.
Parasite survival after treatment was modeled assuming an additive effect between artemisinin and partner drug, and assuming that asexual and early-stage gametocytes were equally susceptible to the ACTs (Supplementary Methods). Assuming that the net parasite replication rate is approximately 12 parasites per 48 hours, the duration of prophylactic protection against new blood-stage infections provided by these ACTs is 35 and 17 days after treatment for MQ and LF, respectively. 
Simulation Process and Modeled Scenarios
The model was coded in Fortran, compiled using the Intel Fortran Compiler, and executed using the QUT high-performance computing platform, which includes a Silicon Graphics International (SGI) Altix XE Computational Cluster. For each modeled scenario, a baseline simulation (phase 1) was conducted to establish transmission within the community and allow acquired immunity (clone specific antibody-mediated) to develop as individuals are repeatedly exposed to P. falciparum infection. Summary parameters, including the entomological inoculation rate (EIR), number of treatments, and prevalence, were monitored during the final 2000 days of the phase 1 simulation to characterize the baseline transmission level. Ten independent simulations were then conducted for another 700 days, using the end point of the phase 1 simulation as the starting point, to ensure that the baseline conditions were maintained. In all cases, there was no significant change in the trajectory of the summary parameters during this period, indicating that the transmission within the village was at equilibrium.
Phase 2 modeling started at the end of the phase 1 simulations for a parallel series of scenarios (Supplementary Figure 2) . On day 50 of each phase 2 simulation, the key parasite was introduced in a randomly selected host. It is assumed that this person was infected by the bite of an infectious mosquito outside the village, returning with a liver-stage infection. The characteristics of this initial host, such as age, multiplicity of infection (MOI) and whether (and when) treatment was sought, were stored for later analysis. Three types of key parasites were investigated: (1) "normal" parasites, that fully expresses PfHRP2; (2) "HRP2-negative" parasites, that express no PfHRP2; and "reduced HRP2" parasites, which produce PfHRP2 at a level equivalent to 25% of the normal parasite. In total, 4 different parasite/RDT scenarios were simulated from the same starting conditions (Supplementary Figure 2) , with 50 simulations conducted for each scenario. Each simulation stopped when the key parasite, introduced at day 50, became extinct or when the end of the simulation time was reached. The simulation time was 700 days, which was sufficient to investigate whether the parasite spread within the community.
The above simulation process was applied to 16 combinations of transmission settings and mosquito feeding/survival characteristics, resulting in a total of 3200 simulations (50 simulations × 4 parasite/RDT scenarios × 4 transmission settings × 4 mosquito feeding/survival characteristics) for each treatment regimen. The impact of malaria control interventions, such as long-lasting impregnated bed nets or indoor residual spraying, was captured in the model by 2 mosquito parameters, along with inherent mosquito behaviors; the proportion of mosquitoes feeding on humans (H) and the probability of mosquitoes surviving the feeding cycle (F). To reflect different vector characteristics and levels of control 2 values for H (0.5 and 0.75) and F (0.5 and 0.65) were simulated, producing 4 mosquito feeding/survival combinations.
Four transmission settings were classified using results from the end of phase 1: The entire simulation procedure was replicated for the 3 treatment regimens, artesunate-MQ with a 50% treatment-seeking rate, artemether-LF with a 50% treatment-seeking rate, and artesunate-MQ with an 80% treatment-seeking rate.
Statistical Analysis
Data processing and statistical analysis was conducted using SPSS software, version 23 (IBM; release 23.0.0.0) and MATLAB software (MathWorks; version R2015b). Summary variables calculated from simulation output included total number of infections caused by the key parasite, time to extinction for the key parasite, prevalence of asexual infection in community, and proportion of infections attributed to the key parasite, EIR, number of symptomatic individuals who sought treatment and were tested using an RDT, number of positive RDT tests, and number of treatments administered within the community. RDT positivity was calculated as follows: (No. of positive RDT results)/(No. of symptomatic individuals seeking treatment) × 100. The success of the introduction for the key parasites was measured by (1) the proportion of simulations wherein the key parasite was transmitted to ≥1 new host and (2) the parasite extinction time. The first of these variables was used as an indicator of the potential for successful introduction, recognizing that stochastic die-out occurs in a proportion of simulations in which the key parasite spreads beyond the initial host. For this reason, the analysis also considered the parasite extinction time. Kaplan-Meier survival analysis using the log-rank test was used to compare the distribution of extinction times, and Cox proportional hazards models were developed to investigate factors associated with extinction time. Binary logistic regression was used to identify factors associated with the spread of the introduced parasite beyond the initial host.
RESULTS

Parasite Transmission
A randomly selected host introduces the key parasite into the population (Supplementary Table 3 ). Key parasites were transmitted to new hosts in only 26.5%, 25.3%, and 25.9% of simulations for normal key parasites, HRP2-reduced key parasites in a community using RDT1, and HRP2-negative key parasites in a community using RDT2, respectively. In contrast, transmission to ≥1 new host occurred in 79.7% of simulations when RDT1 was used and the key parasite was HRP2 negative (Supplementary Figure 3) .
Binary logistic regression analysis of results for the normal, reduced, and HRP2-negative (RDT2) key parasite introductions revealed that receiving treatment and the MOI of the initial host were significant factors for predicting transmission of the key parasite to ≥1 new host (P < .001), whereas treatment regimen and transmission level were not (P > .10). Host age was also a significant factor for simulations with F = 0. Treatment was a significant factor for the transmission of HRP2-negative key parasites for the scenario in which RDT1 was the diagnostic tool (P < .001); ORs were >150 when no treatment was received compared with receiving treatment for all simulation sets. It should be noted that few treatments were received in these scenarios, typically occurring when the host had an MOI >1. The MOI was a significant factor in simulations wherein 50% of symptomatic hosts seek treatment (P < .001); ORs for MOI >1 were 0.544 (95% CI, .342-.865) at F = 0.5 and 0.650 (.452-.935) at F = 0.65. When the treatment regimen involved 80% of symptomatic hosts seeking treatment, MOI was not a significant factor (P > .10), being replaced by transmission level; epidemic and low-endemic settings had 0.211 (95% CI, .125-.392) the odds of transmitting the HRP2-negative parasite to ≥1 new host, compared with the moderate-low and moderate settings (P < .001). The predicted proportions of key parasites transmitted to ≥1 new host are provided in Supplementary  Table 4 .
Cox regression analysis indicated that the hazard of parasite extinction was not significantly influenced by the proportion of mosquitoes feeding on humans (H) (P > .09), or the partner drug (P = .79). However, a variety of other factors were found to influence the hazard of extinction ( Table 1 ). The largest differences in the parasite survival time in the community were seen for the HRP2-negative parasites when RDT1 was used as the sole diagnostic; the median survival time was >650 days, compared with 90 days for the other parasite/RDT combinations ( Figure 2) .
Impact of Introducing a HRP2-Negative Parasite on Parasite Population
Linear mixed-effects modeling using an autoregressive covariance structure indicated that time after introduction, transmission level, and treatment regimen all influenced the percentage of asexual infections in the population caused by the HRP2-negative parasite (P < .001) (Figure 3) . In all transmission settings, the proportion of infections attributed to the HRP2-negative parasite increased over time. Some reversal of this trend was observed in simulations of the 80% treatment-seeking regimen in the moderate-low-and moderate-transmission settings after approximately 400 days. This is probably owing to the complex relationship between acquired clinical immunity and multiclone infections in hosts in these simulation scenarios. Figure 4 illustrates a pattern of reducing RDT positivity over time as the HRP2-negative parasite spreads through communities with a treatment-seeking rate of 50%. When the treatment-seeking rate is 80%, the RDT positivity rate decreases rapidly during the first 300 days after the introduction, after which RDT positivity increases for the moderate-low-and moderate-transmission settings (Figure 4) , reflecting a reduction in HRP2-negative parasites causing symptomatic episodes as acquired immunity develops. In contrast, the number of treatments administered after introduction of the HRP2-negative parasite remained relatively constant over time for all transmission settings ( Figure 5 ). The relative stability in the number of treatments seems to be coincidental, because the increase in transmission caused by lack of treatment is offset by the falling RDT positivity rate.
Clinical Impact of Introducing a HRP-Negative Parasite
Impact of Introducing a HRP2-Negative Parasite on Transmission and
Infection
Two indicators were used to assess transmission within the community after the introduction of the HRP2-negative parasite:
(1) EIR and (2) prevalence of infection with >100 parasites per microliter. The patterns observed in both indicators were similar; prevalence and EIR increased approximately 300 days after the introduction of the HRP2-negative parasite in communities where the treatment-seeking rates is 50%, and slightly earlier for the scenario with artesunate-MQ treatment and an 80% treatment-seeking rate ( Figure 6 and Supplementary Figure 4) . In line with patterns for other indicators, a reversal in this trend occurred after 400 days in simulations for this scenario in the moderate-low-and moderate-transmission scenarios.
DISCUSSION
Parasites lacking PfHRP2 have been detected in several regions of the world, most recently Africa and India [11, 23] . These parasites present a threat to the correct diagnosis of malaria using PfHPR2-based RDTs, potentially resulting in a false-negative and F (probability of mosquitoes surviving the feeding cycle) parameters, as shown. LF(50%), artemether-lumefantrine treatment with a 50% treatment-seeking rate among symptomatic persons; MQ(50%), artesunate-mefloquine (MQ) treatment with a 50% treatment-seeking rate; MQ(80%), artesunate-MQ treatment with an 80% treatment-seeking rate.
parasitological diagnosis, which would deprive the patient of prompt treatment [4] . The results of this modeling study are the first to demonstrate that a newly introduced parasite that produces no PfHRP2 can rapidly spread through a community if a PfHRP2-only RDT is used as the sole diagnostic tool to inform treatment. However, this is not the case when parasites produce a reduced quantity of PfHRP2, equivalent to 25% of normal, or when a combination PfHRP2/P. falciparum-pLDH RDT is used (Figure 2) . The reduced level of PfHRP2 production by parasites was sufficient . Simulation trajectories for rapid diagnostic test (RDT) positivity in the previous 50 days in a village where a Plasmodium falciparum histidine-rich protein 2 (PfHRP2)-detecting P. falciparum-only RDT is used for diagnosis and a PfHRP2-negative parasite was introduced in a randomly selected host. The trajectory of the baseline simulation is displayed for the 200 days before the introduction of the PfHRP2-negative parasite, after which the results of each simulation are displayed. Trajectories are colored according to the values of the H (proportion of mosquitoes feeding on humans) and F (probability of mosquitoes surviving the feeding cycle) parameters, as shown. LF(50%), artemether-lumefantrine treatment with a 50% treatment-seeking rate among symptomatic persons; MQ(50%), artesunate-mefloquine (MQ) treatment with a 50% treatment-seeking rate; MQ(80%), artesunate-MQ treatment with an 80% treatment-seeking rate.
in the model to return positive PfHRP2-detecting RDT results in most symptomatic individuals owing to the low limit of detection of the test, typically high parasitemia and longevity of circulating PfHRP2.
There is uncertainty about whether PfHRP2-detecting RDTs cross-react with PfHRP3. Evidence suggests that some monoclonal antibodies raised against PfHRP2 cross-react with PfHRP3 [24] , but there is only very limited evidence Figure 5 . Simulation trajectories for the number of treatments in the previous 50 days in a village where a Plasmodium falciparum histidine-rich protein 2 (PfHRP2)-detecting P. falciparum-only rapid diagnostic test is used for diagnosis and a PfHRP2-negative parasite was introduced in a randomly selected host. Number of treatments is displayed on a log 10 scale. The trajectory of the baseline simulation is displayed for the 200 days before the introduction of the PfHRP2-negative parasite, after which the results of each simulation are displayed. Trajectories are colored according to the values of the H (proportion of mosquitoes feeding on humans) and F (probability of mosquitoes surviving the feeding cycle) parameters, as shown. LF(50%), artemether-lumefantrine treatment with a 50% treatment-seeking rate among symptomatic persons; MQ(50%), artesunate-mefloquine (MQ) treatment with a 50% treatment-seeking rate; MQ(80%), artesunate-MQ treatment with an 80% treatment-seeking rate.
suggesting that PfHRP2-negative/PfHRP3-positive parasites are positive by certain RDTs [9] . However, such parasites are rarely observed, with parasites more likely to lack either pfhrp3 or both pfhrp2 and pfhrp3 [25, 26] . Additional studies are required to investigate whether different brands of PfHRP2-detecting RDTs react with PfHRP2-negative/PfHRP3-positive parasites. If cross-reactivity does occur, then the modeling results for parasites with reduced levels of PfHRP2 suggest Figure 6 . Simulation trajectories for prevalence of infection (defined as >100 parasites per microliter) in a village where a Plasmodium falciparum histidine-rich protein 2 (PfHRP2)-detecting P. falciparum-only rapid diagnostic test is used as the diagnostic test and a PfHRP2-negative parasite was introduced in a randomly selected host. Data for prevalence of infection represented a census of the community taken every 50 days. The trajectory of the baseline simulation is displayed for the 200 days before the introduction of the PfHRP2-negative parasite, after which the results of each simulation are displayed. Trajectories are colored according to the values of the H (proportion of mosquitoes feeding on humans) and F (probability of mosquitoes surviving the feeding cycle) parameters, as shown. LF(50%), artemether-lumefantrine treatment with a 50% treatment-seeking rate among symptomatic persons; MQ(50%), artesunate-mefloquine (MQ) treatment with a 50% treatment-seeking rate; MQ(80%), artesunate-MQ treatment with an 80% treatment-seeking rate.
that PfHRP2-negative/PfHRP3-positive parasites will not be selected for by using PfHRP2-detecting RDTs.
The findings from the current study indicate that the introduction of PfHRP2-negative parasites will potentially have a severe impact, with increased parasite prevalence, morbidity and transmission rates, and, although not explicit in the model, mortality rates. These changes may occur despite continuation of other control activities such as use of long-lasting impregnated nets and IRS, and are not unexpected, considering that PfHRP2-negative parasites evade a key control measure, namely, treatment of symptomatic patients.
The model results showed that infection of the initial host by >1 parasite was a significant factor in predicting whether the PfHRP2-negative parasite was transmitted, with the proportion of individuals having multiclone infections increasing with transmission intensity. We hypothesize that these multiclone infections explain the result wherein emergence of PfHRP2-negative parasites was slower with increasing transmission intensity. This is because patients coinfected with both PfHRP2-negative and PfHRP2-positive parasites have an increased chance of returning a positive PfHRP2-detecting RDT result owing to the antigen produced by the PfHRP2-positive parasite, thus resulting in treatment and removal of both PfHRP2-negative and PfHRP2-positive parasites. Therefore, lower-transmission settings create the ideal situation for the emergence of drug-sensitive PfHRP2-negative parasites. This hypothesis does not hold if the PfHRP2-negative parasite is drug resistant, and further work is required to clarify the dynamics in this situation.
The model showed that in simulations with higher transmission levels in which 80% of symptomatic hosts seek treatment, the trend for decreased RDT positivity and increased transmission was reversed after approximately 400 days. We hypothesize that this reversal is due to the complex interaction between clinical immunity acquired after repeated exposure to the PfHRP2-negative parasite and hosts having multiclone infections. When the PfHRP2-negative parasite is introduced it is antigenically distinct, causing symptomatic infections that produce false-negative results with PfHRP2-detecting RDTs, go untreated, and spread, leading to increased transmission and repeated exposure for individuals within the community.
Subsequently, individuals develop immunity specific for the PfHRP2-negative parasite, which suppresses the parasite density leading to fewer clinical symptoms and less treatment seeking. Simultaneously, other PfHRP2-positive parasites circulate in the population; therefore, as clinical immunity against the PfHRP2-negative parasite develops, the bulk of symptomatic episodes return to being caused by PfHRP2-positive parasites, as either monoclonal or multiclonal infections containing the PfHRP2-negative parasite, with multiclone infections dominating. This leads to an increase in the RDT positivity rate, resulting in clearance of parasites from the host and a reduction in the reservoir and subsequent transmission of PfHRP2-negative parasites.
One of the challenges currently facing public health practitioners is how to best determine whether HRP2-negative parasites are present in an area. It is important not to jeopardize the effective treatment of patients, while also retaining the most widely available, accessible, and sensitive diagnostic tests. The modeling results illustrate that, against a backdrop of decreasing malaria transmission, it may be difficult to detect the early stages of emergence of these parasites. This calls for vigilant reporting and investigation by National Malaria Control Programme staff of reported suspect malaria infections that repeatedly return negative results using PfHRP2-detecting RDTs but positive results using quality-assured microscopy or pLDH-based RDTs.
As with all modeling studies, the results are sensitive to the assumptions made and these are clearly outlined in the Supplementary Materials. The model is specific to P. falciparum and does not consider the situation where Plasmodium vivax may also be present. The model output would normally be validated using field data, but at present no there are no sufficiently detailed data on the emergence of PfHRP2-negative parasites to perform this validation. However, the patterns observed in the results seem consistent and reasonable based on known epidemiological relationships between malaria disease and transmission.
The current study does not consider the impact of seasonality. Further studies are needed; however, it is expected that the timing of the introduction of the pfhrp2-negative parasite relative to the malaria season would significantly affect the likelihood of the parasite's becoming established in the community, as would the length of the transmission season and the transmission level during the low season.
The results of our study demonstrate that there is a high potential for pfhrp2-negative parasites to spread through a community when detection of P. falciparum malaria depends solely on PfHRP2. The potential impact in terms of increased transmission and untreated malaria infections highlights the potential public health threat that these parasites present, supporting recent efforts by WHO to engage with countries in order to increase surveillance for these parasites.
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